Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells

Article Immunology

Risk of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched Cohort Study

Antonio Leidi et al.

Summary: This study found that seroconversion after SARS-CoV-2 infection provides protection against reinfection lasting at least 8 months. These findings could aid global health authorities in prioritizing vaccine allocation.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Editorial Material Geriatrics & Gerontology

Efficacy and safety of COVID-19 vaccines in older people

Roy L. Soiza et al.

Summary: The safety and efficacy of COVID-19 vaccines in older people are crucial for their success, but there is currently a lack of data. While some Phase III trials have made efforts to recruit older people, those with co-morbidities and frailty have still been largely excluded. Older people, their carers, and healthcare professionals will need to make decisions on vaccination acceptance based on limited evidence.

AGE AND AGEING (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Adaptive immunity to SARS-CoV-2 and COVID-19

Alessandro Sette et al.

Summary: The adaptive immune system, consisting of B cells, CD4(+) T cells, and CD8(+) T cells, plays varying roles in different viral infections and vaccines. Studies are showing that CD4(+) T cells, CD8(+) T cells, and neutralizing antibodies all play a part in controlling SARS-CoV-2 in COVID-19 cases, emphasizing the importance of understanding adaptive immunity in combating the disease.

CELL (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Recent endemic coronavirus infection is associated with less-severe COVID-19

Manish Sagar et al.

Summary: The study suggests that individuals with prior endemic coronavirus infections were tested more frequently for respiratory infections, but had similar rates of acquiring SARS-CoV-2. Additionally, patients with previous endemic coronavirus infections experienced less severe cases of COVID-19.

JOURNAL OF CLINICAL INVESTIGATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

S. F. Lumley et al.

Summary: In a longitudinal study of seropositive and seronegative health care workers undergoing asymptomatic and symptomatic SARS-CoV-2 testing, the presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan et al.

Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.

SCIENCE (2021)

添加到收藏夹

Article Cell Biology

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

Anthony T. Tan et al.

Summary: This study found that early induction of interferon-gamma (IFN-gamma) secreting SARS-CoV-2-specific T cells was present in patients with mild disease and accelerated viral clearance, while rapid induction and quantity of humoral responses were associated with an increase in disease severity. These findings highlight the importance of early functional SARS-CoV-2-specific T cells in both vaccine design and immune monitoring.

CELL REPORTS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection

Elizabeth M. Anderson et al.

Summary: Our research indicates that most individuals had antibodies against other seasonal human coronaviruses before the COVID-19 pandemic. Around 20% of these individuals also had antibodies that cross-reacted with SARS-CoV-2, but these antibodies did not offer protection against SARS-CoV-2 infections or hospitalizations.

CELL (2021)

添加到收藏夹

Letter Medicine, General & Internal

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

Sharon Amit et al.

LANCET (2021)

添加到收藏夹

Article Immunology

Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection

Jianmin Zuo et al.

Summary: The study shows that functional SARS-CoV-2-specific T cell responses are retained and robust at 6 months following infection, with higher T cell responses observed in donors who had experienced symptomatic infection. Levels of nucleoprotein-specific T cells were correlated with nucleoprotein-specific antibody levels, providing insights into the persistence and correlation of immune responses.

NATURE IMMUNOLOGY (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Risk of SARS-CoV-2 reinfection after natural infection

Rosemary J. Boyton et al.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Victoria Jane Hall et al.

Summary: This study investigated whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection. It found that individuals with a previous history of SARS-CoV-2 infection had an 84% lower risk of reinfection, with a median protective effect lasting for 7 months following primary infection.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study

Victoria Jane Hall et al.

Summary: The study aimed to determine the factors associated with vaccine coverage for two COVID-19 vaccines in the UK and to document the vaccine effectiveness of the BNT162b2 mRNA vaccine among healthcare workers. Results showed that the vaccine can prevent both symptomatic and asymptomatic infections in working-age adults, with a vaccine effectiveness of 70% after the first dose and 85% after the second dose.

LANCET (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Nicole Doria-Rose et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil

Nuno R. Faria et al.

Summary: A new variant of concern, P.1, with 17 mutations including three spike protein mutations associated with increased binding to human ACE2 receptors, emerged in Manaus, Brazil between November 2020 and January 2021. Molecular analysis suggests P.1 may be 1.7- to 2.4-fold more transmissible and that previous infection may provide 54 to 79% protection against P.1 infection compared to other lineages. Enhanced global genomic surveillance of such variants is crucial for pandemic response.

SCIENCE (2021)

添加到收藏夹

Review Microbiology

SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19

Alba Grifoni et al.

Summary: This review summarizes recent studies on SARS-CoV-2 T cell epitopes, highlighting the significant correlation between epitope number and antigen size. It also presents an analysis of 1,400 different reported SARS-CoV-2 epitopes and identifies discrete immunodominant regions of the virus and more prevalently recognized epitopes.

CELL HOST & MICROBE (2021)

添加到收藏夹

Article Microbiology

A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses

Alexandra Tauzin et al.

Summary: A single dose of the BNT162b2 mRNA vaccine can be up to 90% effective, with boosted humoral and T cell responses in previously infected individuals. Therefore, spacing doses may help vaccinate more people in conditions of limited vaccine supply.

CELL HOST & MICROBE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Zijun Wang et al.

Summary: Despite challenges posed by COVID-19 variants, convalescent individuals receiving mRNA vaccines exhibit robust and long-lasting immune responses against circulating SARS-CoV-2 variants, providing hope for effective control of the pandemic.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Ugur Sahin et al.

Summary: The BNT162b2 vaccine shows 95% efficacy in preventing COVID-19 by boosting neutralizing antibody titres and activating specific T cell responses. The vaccine-induced immune response is broad and stable, lasting for a prolonged period, providing good coverage against various SARS-CoV-2 variants.

NATURE (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

Robert W. Frenck et al.

Summary: The BNT162b2 vaccine showed favorable safety profile and a greater immune response in 12-to-15-year-old recipients compared to young adults, and demonstrated high effectiveness against Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants

Amarendra Pegu et al.

Summary: The study assessed the impact of SARS-CoV-2 variants on antibody responses induced by the mRNA vaccine over 7 months, showing that most individuals maintained binding and functional antibodies against variants, with B.1.351 having the lowest antibody recognition.

SCIENCE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan

Cesheng Li et al.

Summary: The study found that the positive rate of RBD-IgG antibody in convalescent COVID-19 patients exceeded 70% at 12 months post-diagnosis, with the RBD-IgG level decreasing over time. Male and older patients showed stronger immune responses.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Medicine, Research & Experimental

FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a mufti-state health system

Colin Pawlowski et al.

Summary: The study analyzed the effectiveness of BNT162b2 and mRNA-1273 vaccines in preventing COVID-19 in a real-world setting, and found that both vaccines were highly effective in reducing SARS-CoV-2 infection rates and lowering the burden of COVID-19 on the healthcare system.

MED (2021)

添加到收藏夹

Article Cell Biology

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

Kristen W. Cohen et al.

Summary: The study reveals that COVID-19 patients have durable broad-based immune responses, including the continuous generation of antibodies, memory B cells, and polyfunctional T cells, which help to rapidly generate antibody responses against virus re-exposure or vaccination.

CELL REPORTS MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

Laith J. Abu-Raddad et al.

Summary: The study shows that reinfection is rare in Qatar's young and international population, with natural infection providing strong protection against reinfection with an estimated efficacy of around 95% for at least seven months. Reinfections are often less severe than primary infections.

ECLINICALMEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences